264 related articles for article (PubMed ID: 18369818)
1. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
2. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
4. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
7. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
[TBL] [Abstract][Full Text] [Related]
8. Telomerase as a universal tumor-associated antigen for cancer immunotherapy.
Vonderheide RH
Oncogene; 2002 Jan; 21(4):674-9. PubMed ID: 11850795
[TBL] [Abstract][Full Text] [Related]
9. In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.
Chen L; Liang GP; Tang XD; Chen T; Cai YG; Fang DC; Yu ST; Luo YH; Yang SM
Biochem Biophys Res Commun; 2006 Dec; 351(4):927-34. PubMed ID: 17097054
[TBL] [Abstract][Full Text] [Related]
10. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
Pang JX
Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients.
Titu LV; Loveday RL; Madden LA; Cawkwell L; Monson JR; Greenman J
Oncol Rep; 2004 Oct; 12(4):871-6. PubMed ID: 15375515
[TBL] [Abstract][Full Text] [Related]
12. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
[TBL] [Abstract][Full Text] [Related]
13. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors.
Frolkis M; Fischer MB; Wang Z; Lebkowski JS; Chiu CP; Majumdar AS
Cancer Gene Ther; 2003 Mar; 10(3):239-49. PubMed ID: 12637945
[TBL] [Abstract][Full Text] [Related]
15. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.
Vonderheide RH; Schultze JL; Anderson KS; Maecker B; Butler MO; Xia Z; Kuroda MJ; von Bergwelt-Baildon MS; Bedor MM; Hoar KM; Schnipper DR; Brooks MW; Letvin NL; Stephans KF; Wucherpfennig KW; Hahn WC; Nadler LM
Cancer Res; 2001 Dec; 61(23):8366-70. PubMed ID: 11731409
[TBL] [Abstract][Full Text] [Related]
16. Telomerase as a universal tumor antigen for cancer vaccines.
Beatty GL; Vonderheide RH
Expert Rev Vaccines; 2008 Sep; 7(7):881-7. PubMed ID: 18767939
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.
Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O
Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669
[TBL] [Abstract][Full Text] [Related]
18. Immunization with truncated sequence of Telomerase Reverse Transcriptase induces a specific antitumor response in vivo.
Qiu J; Li GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W
Acta Oncol; 2007; 46(7):961-8. PubMed ID: 17917827
[TBL] [Abstract][Full Text] [Related]
19. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients.
Danet-Desnoyers GA; Luongo JL; Bonnet DA; Domchek SM; Vonderheide RH
Exp Hematol; 2005 Nov; 33(11):1275-80. PubMed ID: 16263411
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
